Direct comparison
Recruitment Vendor vs. In-House: Cost & Speed
Clinical trial recruitment company vs. in-house recruitment: cost structure, speed to enrollment, rare-population reach, and control tradeoffs compared.
Side-by-side comparison
| Dimension | Recruitment Vendor | In-House Recruitment |
|---|---|---|
| Cost structure | Variable, activity-based fee layered on top of trial budget: cost-per-lead, cost-per-screened-candidate, cost-per-randomized-participant, a fixed program fee, or an embedded-staff (Functional Service Provider-style) arrangement. Cost is visible per line item but scales with volume and is negotiated up front. | Largely fixed and often already sunk: coordinator/recruiter salary and benefits, institutional overhead, and any local advertising the site already budgets for. Marginal cost of an additional recruitment push is low if staff capacity exists, but idle capacity between studies is a real cost the trial budget doesn't itemize. |
| Speed to enrollment | Vendors with existing creative, media-buying, and screening infrastructure can typically stand up a campaign faster than a site building outreach from nothing, and multi-site/multi-country vendors can scale a campaign up or down as enrollment data comes in. | Ramp-up depends entirely on existing staff bandwidth and relationships (referring clinicians, patient registries the site already maintains). Fast when a site has a strong existing referral base for the target condition; slow when that base doesn't exist and has to be built from scratch mid-trial. |
| Specialized or rare-population reach | Digital targeting, EHR- and claims-based pre-identification, and multi-study search platforms can reach beyond a single institution's existing patient population — the main reason sponsors bring in a vendor for a rare disease or a hard-to-identify phenotype. | Bounded by the site's own catchment area, referral network, and existing patient registries. Effective for common conditions with strong local prevalence; a structural limitation for rare diseases or narrowly defined eligibility criteria. |
| Control and oversight burden | Requires active vendor management: contract negotiation, data-handling and (where PHI is involved) HIPAA Business Associate Agreement terms, IRB/REC review of all vendor-produced materials, and ongoing monitoring so incentives (e.g., lead volume) stay aligned with actual enrollment quality rather than volume alone. | Participant contact and screening data stay inside systems the site or sponsor already controls, with no separate data-transfer or BAA negotiation for the recruitment function itself — but the site still needs the recruiter capacity and screening rigor to do the work well. |
| Regulatory responsibility | Unchanged: the sponsor retains ultimate responsibility for how participants were identified, approached, and consented, consistent with the delegation principle in ICH E6(R2) Section 5.2 and, in the US, 21 CFR 312.52. Contracting out recruitment changes who performs the work, not who is accountable for it. | Same underlying responsibility, held directly rather than delegated — no separate delegation-of-duties documentation is needed for the recruitment function itself, but the site or sponsor bears the full operational burden as well as the accountability. |
| Best fit | Rare or narrowly defined populations, aggressive enrollment timelines, multi-site or multi-country trials, or any protocol where the internal team lacks a specific capability (media buying at scale, EHR-based pre-identification, multilingual creative). | Common conditions with strong local prevalence, a site with an established referral network or patient registry for the target population, and trials where the timeline allows organic enrollment growth. |
Common questions
FAQ
Does hiring a recruitment company reduce a sponsor's regulatory responsibility?+
No. Consistent with the delegation principle in ICH E6(R2) Section 5.2 and, in the US, 21 CFR 312.52, contracting out recruitment changes who performs the work, not who is accountable for it. The sponsor retains overall responsibility for how participants were identified, approached, and consented, and for the quality and integrity of the trial as a whole.
Is a blended model — vendor plus in-house recruitment — common?+
Yes. Many trials use internal staff and existing referral networks as the first-line recruitment channel and bring in a vendor to fill a specific gap the internal team cannot cover, such as EHR-based pre-identification for a rare condition, multilingual creative for a multi-country trial, or paid digital media at a scale the site cannot run itself. The choice is rarely strictly binary.
Does using a recruitment vendor change IRB or REC review requirements?+
No. Any direct advertising or recruitment material intended for prospective participants — ad copy, images, video, study websites — still requires IRB or REC review and approval before use, regardless of whether a site, a sponsor, or a contracted vendor produced it.
What data-handling agreement does a recruitment vendor typically need?+
A vendor that accesses protected health information or electronic health record data for pre-identification purposes in the US typically requires a HIPAA Business Associate Agreement (BAA) in addition to the underlying services contract; comparable data-protection agreements apply under other jurisdictions' frameworks, such as GDPR in the EU, when a vendor processes personal data on the sponsor's or site's behalf.
Going deeper
